Figure 1 Traditional and next-generation therapies for PAH. Traditional therapy for PAH is
based on combining two or three vasodilators targeting endothelin 1, NO, and prostacyclin …

Pulmonary arterial hypertension (PAH) is a rare and life-threatening disease due to
vasoconstriction, vascular remodelling, and thrombosis in situ within the pulmonary …

Sotatercept is the first successful therapy to make it through phase 3 to regulatory
submission in pulmonary arterial hypertension that is not proposed to work via vasodilatory …

Background Pulmonary arterial hypertension is characterized by pulmonary vascular
remodeling, cellular proliferation, and poor long-term outcomes. Dysfunctional bone …

Pulmonary arterial hypertension (PAH) results from proliferative remodeling and narrowing
of the pulmonary vasculature. Sotatercept is a first-in-class fusion protein that has recently …

Introduction: PAH is characterized by pulmonary vascular remodeling and right ventricular
dysfunction. Sotatercept acts as a reverse remodeling agent proposed to rebalance anti-and …

Pulmonary arterial hypertension is a progressive disease characterized by elevated blood
pressure in the pulmonary arteries. Symptoms include shortness of breath, dizziness …

Background Pulmonary arterial hypertension is a progressive disease involving proliferative
remodeling of the pulmonary vessels. Despite therapeutic advances, the disease-associated …

Introduction: Sotatercept is a first-in-class activin signaling inhibitor under study for PAH. In
the phase 2 PULSAR and phase 3 STELLAR trials, sotatercept added to standard PAH …

Introduction Although the prevalence of pulmonary arterial hypertension (PAH) is low,
mortality is high. In PAH, there is a down-regulation of the bone morphogenetic protein …